The hybrid injectables HA-CaHA and HA-CaHA-L are effective and safe for up to 1 year for the treatment of midface volume deficit.
Surgery Partners (NASDAQ: SGRY) had a crushingly bad day on the stock market Monday. Investors eagerly traded out of the ...
InfuSystem (INFU) is poised for strong growth with rising profits, margin gains, and expansion in patient services. Read here ...
From a high of around P2,400 per share in early 2024, the stock has fallen to roughly P1,450 by November 2025, which ...
Yet the future could still be bright for California-based Rivian Automotive (NASDAQ: RIVN). That's because the company is ...
Several new serums promise to reverse weight loss-induced sagging. Can they possibly work? We’ve entered a new divide in ...
11hon MSN
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth
Stolper provided an update on 2026 Medicare reimbursement: "Our initial analysis in July of all the various variables of the proposal indicated that RadNet on roughly $2 billion of revenue will ...
Understand what a fiduciary designation entails and how it sets these financial advisors apart Written By Written by Staff Senior Editor, Buy Side Miranda Marquit is a staff senior personal finance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback